News
2023
-
Group Company
Products
December 1, 2023
-
Notification of the Approval of Home Self-injection Guidance and Management Fees and the Derestriction of the Dosing Period for NanozoraⓇ
-
Holdings
Finance
November 24, 2023
-
Announcement of Implementation of MBO and Recommendation for Tender Offer
-
Holdings
Finance
November 24, 2023
-
Announcement of Revision of Dividend Forecast for the Fiscal Year Ending March 31, 2024 (No Dividend)
-
Holdings
Finance
November 10, 2023
-
The 2nd Quarter of Fiscal 2023 Financial Statements
-
Holdings
Finance
November 10, 2023
-
Reference Data of The 2nd Quarter of Fiscal 2023 Financial Statements
-
Holdings
Finance
August 7, 2023
-
Notice Concerning Determination of Details of Stock Options (Stock Acquisition Rights)
-
Holdings
Finance
August 4, 2023
-
The 1st Quarter of Fiscal 2023 Financial Statements
-
Holdings
Finance
August 4, 2023
-
Reference Data of The 1st Quarter of Fiscal 2023 Financial Statements
-
Group Company
R&D
August 1, 2023
-
Notification of Approval to Manufacture and Market Nanozora® 30mg Autoinjectors for S.C. Injection in Japan
-
Holdings
Finance
June 29, 2023
-
Notice Concerning Issuance of Stock Options (Stock Acquisition Rights)
-
Holdings
Finance
June 29, 2023
-
Notice of Resolution at the 12th Ordinary General Meeting of Shareholders
-
Group Company
Corporate
June 21, 2023
-
Taisho Pharmaceutical and Biolinq Announce Strategic Collaboration and Exclusive License Agreement in Japan
-
Holdings
Finance
May 11, 2023
-
Financial Statements for Fiscal 2022
-
Holdings
Finance
May 11, 2023
-
Reference Data of Financial Statements for Fiscal 2022
-
Holdings
Finance
February 9, 2023
-
The 3rd Quarter of Fiscal 2022 Financial Statements
-
Holdings
Finance
February 9, 2023
-
Reference Data of The 3rd Quarter of Fiscal 2022 Financial Statements
-
Holdings
Finance
February 9, 2023
-
Notice of Revision of Forecasts for the Fiscal Year Ending March 31, 2023